- Home
- DAWN vs GB Comparison
DAWN vs GB Comparison
Compare DAWN & GB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- GB
- Stock Information
- Founded
- DAWN 2018
- GB 1980
- Country
- DAWN United States
- GB Switzerland
- Employees
- DAWN N/A
- GB N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- GB EDP Services
- Sector
- DAWN Health Care
- GB Technology
- Exchange
- DAWN Nasdaq
- GB Nasdaq
- Market Cap
- DAWN 1.3B
- GB 1.5B
- IPO Year
- DAWN 2021
- GB N/A
- Fundamental
- Price
- DAWN $12.15
- GB $6.80
- Analyst Decision
- DAWN Strong Buy
- GB Buy
- Analyst Count
- DAWN 7
- GB 1
- Target Price
- DAWN $36.33
- GB $6.00
- AVG Volume (30 Days)
- DAWN 1.1M
- GB 84.5K
- Earning Date
- DAWN 02-24-2025
- GB 02-26-2025
- Dividend Yield
- DAWN N/A
- GB N/A
- EPS Growth
- DAWN N/A
- GB 422.66
- EPS
- DAWN N/A
- GB 0.21
- Revenue
- DAWN $101,953,000.00
- GB $517,909,882.00
- Revenue This Year
- DAWN N/A
- GB $20.57
- Revenue Next Year
- DAWN $34.82
- GB $11.33
- P/E Ratio
- DAWN N/A
- GB $32.51
- Revenue Growth
- DAWN N/A
- GB 21.84
- 52 Week Low
- DAWN $11.13
- GB $4.14
- 52 Week High
- DAWN $18.07
- GB $8.00
- Technical
- Relative Strength Index (RSI)
- DAWN 44.59
- GB 39.34
- Support Level
- DAWN $11.93
- GB $6.89
- Resistance Level
- DAWN $13.53
- GB $7.70
- Average True Range (ATR)
- DAWN 0.56
- GB 0.40
- MACD
- DAWN 0.03
- GB -0.14
- Stochastic Oscillator
- DAWN 35.21
- GB 5.88
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About GB Global Blue Group Holding AG
Global Blue Group Holding AG offers a seamless shopping and payment journey for tourists and also provides a wide range of Added-Value Payment Solutions for all the stakeholders involved, including retailers and international shoppers. The company connect thousands of retailers, acquirers, and hotels with nearly 80 million consumers across more than 50 countries, in three industries: Tax Free Shopping, Payments and Post-Purchase solutions.